Pioglitazone/metformin adduct regulates insulin secretion and inhibits high glucose‐induced apoptosis via p21‐p53‐MDM2 signaling in INS‐1 cells
Pioglitazone/metformin adduct is a novel compound synthesized from pioglitazone and metformin combined at a molar mass ratio of 1:1. The aim of this study was to investigate the effects of pioglitazone/metformin adduct on high glucose‐induced insulin secretion and apoptosis in INS‐1 cells. Western b...
Saved in:
Published in | Journal of cellular biochemistry Vol. 119; no. 7; pp. 5449 - 5459 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.07.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pioglitazone/metformin adduct is a novel compound synthesized from pioglitazone and metformin combined at a molar mass ratio of 1:1. The aim of this study was to investigate the effects of pioglitazone/metformin adduct on high glucose‐induced insulin secretion and apoptosis in INS‐1 cells. Western blot and CCK8 analyses showed that the death rate of INS‐1 cells increased in response to glucose treatment in a concentration‐dependent manner. ELISA assays and Western blot analyses showed that insulin secretion peaked following treatment with glucose concentration at 33.33 mM. Treatment of INS‐1 cells with 1 μM pioglitazone/metformin adduct in the presence of 33.33 mM glucose greatly improveded the levels of insulin and apoptosis rates compared to those of the control group. Analysis of mechanism underlying these effects revealed the involvement of the p21‐p53‐MDM2 signaling pathway. Our results indicate that pioglitazone/metformin adduct is superior to pioglitazone and/or metformin in regulating high glucose‐induced insulin secretion and apoptosis in INS‐1 cells.
This article provide and validate a new adduct which is effective to insulin secretion and inhibits apoptosis under high‐glucose treatment. It has great value. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0730-2312 1097-4644 |
DOI: | 10.1002/jcb.26701 |